Stay updated on Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial
Sign up to get notified when there's something new on the Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial page.

Latest updates to the Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThis page now shows Revision: v3.5.4, replacing the previous v3.5.3 revision. This indicates a small update to the page record without altering the study details or required actions for participants.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check30 days agoChange DetectedThis change updates the ClinicalTrials.gov page revision version from v3.5.2 to v3.5.3, reflecting a site/software metadata update rather than a change to the underlying study record content.SummaryDifference0.1%

- Check37 days agoChange DetectedSite revision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check66 days agoChange Detected- Version history updated: Revision v3.5.0 added; Revision v3.4.3 removed.SummaryDifference0.1%

- Check80 days agoChange DetectedVersion bump from v3.4.2 to v3.4.3; study details and user-facing content remain the same.SummaryDifference0.1%

- Check101 days agoChange DetectedAdded 'Gastric cancer' as a keyword and included the Genetic and Rare Diseases Information Center under Resources. Page revision updated from v3.4.1 to v3.4.2.SummaryDifference0.2%

Stay in the know with updates to Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial page.